Purpose: This study investigates potential causal links between circulating metabolites and thyroid cancer risk using genetic instrumental variables. Methods: Summary data from a genome-wide association study (GWAS) on circulating metabolites (N=7,824)and thyroid cancer GWAS summary data, including 1,054 cases and 490,920 controls, were analyzed. Using genetic variants and the inverse variance weighted method, the study assessed the causal impact of metabolites on thyroid cancer risk and identified affected metabolite levels. Results: Isovalerylcarnitine and but yrylcarnitine demonstrated significant positive associations with the risk of thyroid cancer, exhibiting odds ratios of 6.11 (95% CI: 1.26 to 29.71) and 1.77 (95% CI: 1.05 to 2.96), respectively. The research uncovered a nuanced relationship between thyroid cancer and seven metabolites: glutamine, citrulline, ornithine, 4-hydroxyhippurate, stearamide, N1-methyl-3-pyridone-4-carboxamide, and taurolithocholate 3-sulfate.Conclusion: Our research reveals potential links between various metabolites and thyroid cancer risk, enhancing our understanding of the role circulating metabolites play in the etiology of thyroid cancer.[Disclosure of COI by Responsible researcher] Lead presenter is not the Responsible researcher.[Lead presenter] We have no financial relationships to disclose.
